In conclusion, our findings indicate that BCATc Inhibitor 2 protects against oleic acid-induced lipogenesis and apoptosis in hepatic cells and demonstrate that BCATc Inhibitor 2 is a promising drug for the treatment of NAFLD in clinic. Here, BCAT1 is linked to metabolic dysfunction-associated steatotic liver disease.